On the negative side, a phase III study combining an IDO1-selective competitive inhibitor with an anti-PD-1 monoclonal antibody failed to provide significant therapeutic gain in patients with metastatic melanoma [56,57,58,59]. This evidence concerns the gene IDO1 and metastatic melanoma.